AAD

(redirected from Anti-Arrhythmic Drugs)
Also found in: Medical.
AcronymDefinition
AADAustralian Antarctic Division (Australia's Antarctic program)
AADAzure Active Directory (Microsoft)
AADAmerican Academy of Dermatology
AADAlmost a Doctor
AADAverage Absolute Deviation
AADAcid-Ash Diet (nutrition)
AADAscii Adjust before Division
AADActive Acoustic Device
AADAdvanced Agile Device
AADAccess to Archival Database
AADAutodesk Architectural Desktop
AADAccess to Archival Databases (US NARA)
AADAdministrative Accompanying Document (various organizations)
AADAviation Accident Database (US NTSB)
AADAccompanying Administrative Document (UK)
AADAutomatic Activation Device
AADAntibiotic-Associated Diarrhea
AADAssistant Area Director (various locations)
AADAmerican Academy of Diplomacy (est. 1983; Washington, DC)
AADAdditional Authenticated Data (WPA-CCMP encryption)
AADAcademic Achievement Division (various locations)
AADArmed and Dangerous (video game)
AADArbeids- og Administrasjonsdepartementet (Norwegian: Ministry of Labour and Government Administration)
AADAdvanced Agility Dog (dog agility title)
AADAnti-Arrhythmic Drugs
AADAdvanced Air Defense (missile intercept system)
AADArgumentation et Analyse du Discours (French: Argumentation and Discourse Analysis)
AADAmerican Annals of the Deaf
AADAssistant Athletic Director
AADArmy Air Defense
AADAir Assault Division
AADAnalog Analog Digital (audio CD recording format, recording/mixing/mastering)
AADAdvanced Academic Degree
AADAdvanced Animal Diagnostics
AADAnnual Aggregate Deductible (insurance)
AADArea Air Defence
AADAutomotive Analysis Division (University of Michigan)
AADAssigned Altitude Deviation
AADAlabama Association of the Deaf
AADAide et Assistance à Domicile (French: Home Help and Support)
AADArchive of Art and Design
AADAnalog Alignment Diskette
AADAssociate Art Director
AADAdvanced Ammunition Depot
AADAuthorized AutoCAD Dealer
AADAutomated Application Development (software development)
AADAdmission And Disposition
AADAngolan Action for Development (Angola)
AADAffirmative Action Division (various local governments)
AADAlpha-Aminoadipic Acid
AADAustin Association of the Deaf (Texas)
AADAttitude Anomaly Detector
AADAmerican Academy of Denturity
AADAlaska Association of the Deaf
AADArkansas Association of the Deaf, Inc.
AADAppeals Arbitration Division (ICAS)
AADAdvanced Access and Disablement
AADAutomatic Actuation Device
AADAccess Approval Document
AADAircraft Armament Division
AADAutomatic Adaptive Detection
AADAllgemeiner Anlagedienst
AADAirborne Assault Division
AADAllowance Appendix Documentation
AADAcronym/Abbreviation Definition
AADArmoured Amphibious Dozer
AADAll About Dollars
AADAdditive Accumulative of Damages
AADAdvanced Alloy Development
AADAtomic Absorption Detector
AADAcquisition Activities Division
AADAdvanced Acoustic Decoy
AADAnalysis & Application Division
AADArmy Automation Directorate
AADAdvanced Alloy Duct (test)
References in periodicals archive ?
Moreover, 40%-60% of the prevalent US atrial fibrillation patient population (estimated at 4-5m patients) fail at least one anti-arrhythmic drug, cardioversion or catheter based intervention.
Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches.
Major Finding: Patients treated with catheter ablation or an anti-arrhythmic drug had a similar atrial fibrillation burden during 2 years of follow-up.
But heart patients are often on more than on medication, including blood pressure-lowering drugs, anti-arrhythmic drugs (for abnormal heart rhythms), and other medicines for non-heart related conditions.
The atrial fibrillation market report provides market size estimates (Revenue USD million - 2013 to 2020) for key market segments based on treatment type (pharmacological - anti-arrhythmic drugs, anti-coagulant drugs and non-pharmacological - catheter ablation based on cryoablation, HIFU, laser, microwave and radiofrequency, maze surgery, and electric cardioversion), and forecasts growth trends (CAGR% - 2016 to 2020).
Anti-arrhythmic drugs, such as digoxin, beta-blockers, calcium channel blockers, amiodarone, flecainide and propafenone.
Patients are most often treated with anti-arrhythmic drugs, which can be associated with adverse side effects.
He adds that the guidelines also suggest that for selected patients, chronic AF may be prevented by anti-arrhythmic drugs such as dronedarone (Multaq) and certain invasive procedures.